# Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

> **NCT06364176** · PHASE2 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 42 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Losartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06364176
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-03
- **Primary completion:** 2027-05
- **Final completion:** 2027-10
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364176, "Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06364176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*